Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free RVX Stock Alerts

Resverlogix (RVX) Competitors

Resverlogix logo
C$0.10 +0.01 (+5.00%)
As of 07/24/2026 01:50 PM Eastern
Compare

RVX vs. HBP, SCYB, COM, NVH, and IGX

Should you buy Resverlogix stock or one of its competitors? MarketBeat compares Resverlogix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Resverlogix include Helix BioPharma (HBP), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), and IntelGenx Technologies (IGX). These companies are all part of the "biotechnology" industry.

How does Resverlogix compare to Helix BioPharma?

Helix BioPharma (TSE:HBP) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Helix BioPharma has a beta of 0.431088, meaning that its stock price is 57% less volatile than the broader market. Comparatively, Resverlogix has a beta of 0.410328, meaning that its stock price is 59% less volatile than the broader market.

0.0% of Helix BioPharma shares are owned by institutional investors. Comparatively, 0.0% of Resverlogix shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by company insiders. Comparatively, 42.7% of Resverlogix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Resverlogix's return on equity of 6.67% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -21.54% -279.98%
Resverlogix N/A 6.67%-34.90%

In the previous week, Helix BioPharma's average media sentiment score of 0.00 equaled Resverlogix'saverage media sentiment score.

Company Overall Sentiment
Helix BioPharma Neutral
Resverlogix Neutral

Helix BioPharma is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A
ResverlogixN/AN/A-C$2.81M-C$0.02N/A

Summary

Resverlogix beats Helix BioPharma on 7 of the 8 factors compared between the two stocks.

How does Resverlogix compare to Scythian Biosciences?

Scythian Biosciences (CVE:SCYB) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Resverlogix's return on equity of 6.67% beat Scythian Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Scythian BiosciencesN/A N/A N/A
Resverlogix N/A 6.67%-34.90%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scythian BiosciencesN/AN/AN/AN/AN/A
ResverlogixN/AN/A-C$2.81M-C$0.02N/A

In the previous week, Scythian Biosciences' average media sentiment score of 0.00 equaled Resverlogix'saverage media sentiment score.

Company Overall Sentiment
Scythian Biosciences Neutral
Resverlogix Neutral

0.0% of Resverlogix shares are owned by institutional investors. 42.7% of Resverlogix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Resverlogix beats Scythian Biosciences on 3 of the 4 factors compared between the two stocks.

How does Resverlogix compare to 138267 (COM.TO)?

138267 (COM.TO) (TSE:COM) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

In the previous week, 138267 (COM.TO)'s average media sentiment score of 0.00 equaled Resverlogix'saverage media sentiment score.

Company Overall Sentiment
138267 (COM.TO) Neutral
Resverlogix Neutral

0.0% of Resverlogix shares are held by institutional investors. 42.7% of Resverlogix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Resverlogix's return on equity of 6.67% beat 138267 (COM.TO)'s return on equity.

Company Net Margins Return on Equity Return on Assets
138267 (COM.TO)N/A N/A N/A
Resverlogix N/A 6.67%-34.90%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
138267 (COM.TO)N/AN/AN/AN/AN/A
ResverlogixN/AN/A-C$2.81M-C$0.02N/A

Summary

Resverlogix beats 138267 (COM.TO) on 3 of the 4 factors compared between the two stocks.

How does Resverlogix compare to Novoheart?

Novoheart (CVE:NVH) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

0.0% of Resverlogix shares are owned by institutional investors. 42.7% of Resverlogix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Novoheart's average media sentiment score of 0.00 equaled Resverlogix'saverage media sentiment score.

Company Overall Sentiment
Novoheart Neutral
Resverlogix Neutral

Resverlogix has lower revenue, but higher earnings than Novoheart. Novoheart is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoheartC$423.50K236.08-C$7.17M-C$0.04N/A
ResverlogixN/AN/A-C$2.81M-C$0.02N/A

Resverlogix's return on equity of 6.67% beat Novoheart's return on equity.

Company Net Margins Return on Equity Return on Assets
NovoheartN/A N/A N/A
Resverlogix N/A 6.67%-34.90%

Summary

Resverlogix beats Novoheart on 6 of the 8 factors compared between the two stocks.

How does Resverlogix compare to IntelGenx Technologies?

Resverlogix (TSE:RVX) and IntelGenx Technologies (CVE:IGX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Resverlogix has higher earnings, but lower revenue than IntelGenx Technologies. IntelGenx Technologies is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResverlogixN/AN/A-C$2.81M-C$0.02N/A
IntelGenx TechnologiesC$1.75M49.95-C$11.74M-C$0.08N/A

Resverlogix's return on equity of 6.67% beat IntelGenx Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
ResverlogixN/A 6.67% -34.90%
IntelGenx Technologies N/A N/A N/A

0.0% of Resverlogix shares are held by institutional investors. 42.7% of Resverlogix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Resverlogix's average media sentiment score of 0.00 equaled IntelGenx Technologies'average media sentiment score.

Company Overall Sentiment
Resverlogix Neutral
IntelGenx Technologies Neutral

Summary

Resverlogix beats IntelGenx Technologies on 6 of the 8 factors compared between the two stocks.

Get Resverlogix News Delivered to You Automatically

Sign up to receive the latest news and ratings for RVX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RVX vs. The Competition

Export
MetricResverlogixBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$33.28MC$434.82MC$6.88BC$12.48B
Dividend Yield7.02%3.90%2.67%6.19%
P/E Ratio-5.253.1627.0836.95
Price / SalesN/A6,592.20495.869.44
Price / Cash132.5013.1350.5482.29
Price / Book-0.3583.7010.284.39
Net Income-C$2.81M-C$96.07MC$3.60BC$299.09M
7 Day PerformanceN/A-0.68%-1.27%0.61%
1 Month PerformanceN/A-1.09%-0.36%1.06%
1 Year Performance-22.22%56.10%18.31%30.89%

Resverlogix Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RVX
Resverlogix
N/AC$0.11
+5.0%		N/A-32.3%C$33.28MN/AN/A19
HBP
Helix BioPharma
N/AC$1.44
flat		N/A+35.2%C$109.98MN/AN/A9
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%		N/A+0.0%C$102.38MN/AN/AN/A
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/AN/AN/A
NVH
Novoheart
N/AC$0.53
+1.9%		N/A+0.0%C$99.98MC$423.50KN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:RVX) was last updated on 7/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel